Adlai Nortye (ANL) Stock Price, News & Analysis

Company Overview

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s research and development activities center on oncology and immuno-oncology, with the goal of addressing unmet needs in the treatment of solid tumors.

Adlai Nortye’s lead candidate is buparlisib, also known as AN2025, an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor being developed for oncology indications, including head and neck cancer. The company is also advancing additional investigational programs intended to target cancer-related biological pathways and potentially support combination treatment approaches.

Founded in China, Adlai Nortye has pursued a global development strategy, conducting activities across China and the United States and seeking to develop its therapies for international markets. Its products remain investigational and are subject to clinical testing and regulatory review.

Key Stats

• Today's Range: $15.97 to $16.95
• 50-Day Range: $10.63 to $16.60
• 52-Week Range: $0.88 to $17.25
• Volume: 92,805 shs
• Average Volume: 373,972 shs
• Market Capitalization: $1.03 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.50
• Consensus Rating: Moderate Buy

Adlai Nortye Stock Analysis - MarketRank™

Adlai Nortye scored higher than 50% of companies evaluated by MarketBeat, and ranked 546th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Adlai Nortye has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Adlai Nortye has a consensus price target of $29.50, representing about 84.7% upside from its current price of $15.97.

Amount of Analyst Coverage

Adlai Nortye has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adlai Nortye are expected to decrease in the coming year, from ($0.19) to ($0.34) per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.40% of the float of Adlai Nortye has been sold short.

Short Interest Ratio / Days to Cover

Adlai Nortye has a short interest ratio ("days to cover") of 26.81, which indicates bearish sentiment.

Change versus previous month

Short interest in Adlai Nortye has recently decreased by 4.07%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adlai Nortye does not currently pay a dividend.

Dividend Growth

Adlai Nortye does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.92

News Sentiment

Adlai Nortye has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Adlai Nortye this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for ANL on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Adlai Nortye insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $164,635.00 in company stock.

Percentage Held by Institutions

35.21% of the stock of Adlai Nortye is held by institutions.

Company Calendar

• Today: 9/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ANL
• Previous Symbol: NASDAQ:ANL
• CIK: 1944552
• Web: www.adlainortye.com
• Phone: 848-230-7430
• Fax: N/A
• Employees: 109
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Adlai Nortye: $29.50
• High Price Target: $49.00
• Low Price Target: $20.00
• Potential Upside/Downside: +83.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 9.55
• Quick Ratio: 0.65

Sales & Book Value

• Annual Sales: $5 million
• Price / Sales: 206.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.21) per share
• Price / Book: -76.51

Miscellaneous

• Outstanding Shares: 64,400,000
• Free Float: N/A
• Market Cap: $1.03 billion
• Optionable: Not Optionable
• Beta: 1.04